Helen I. McDonald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helen I. McDonald has a total of 334 co-authors. Here are the top co-authors by number of shared publications:
- Christopher T. Rentsch
Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA
36 shared publications - Rohini Mathur
Affiliation Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom
35 shared publications - Laurie A. Tomlinson
Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
33 shared publications - Liam Smeeth
Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
32 shared publications - Helen J Curtis
Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK
30 shared publications - Alex J. Walker
University of Oxford
29 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 6 (11) , 100775
Long-term survival after invasive pneumococcal disease: a matched cohort study using electronic health records in England
- 21 November 2025
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 6 (11) , 100775
Open AccessLong-term survival after invasive pneumococcal disease: a matched cohort study using electronic health records in England
- Open Access
- 16 December 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 5, 243
Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
On March 11th 2020, the World Health Organization characterised COVID-19 as a pandemic. Responses to containing the spread of the virus have relied heavily on policies involving restricting contact between people. Evolving policies regarding shielding and individual choices about restricting social contact will rely heavily on perceived risk of poor outcomes from COVID-19. In order to make informed decisions, both individual and collective, good predictive models are required. For outcomes related to an infectious disease, the performance of any risk prediction model will depend heavily on the underlying prevalence of infection in the population of interest. Incorporating measures of how this changes over time may result in important improvements in prediction model performance. This protocol reports details of a planned study to explore the extent to which incorporating time-varying measures of infection burden over time improves the quality of risk prediction models for COVID-19 death in a large population of adult patients in England. To achieve this aim, we will compare the performance of different modelling approaches to risk prediction, including static cohort approaches typically used in chronic disease settings and landmarking approaches incorporating time-varying measures of infection prevalence and policy change, using COVID-19 related deaths data linked to longitudinal primary care electronic health records data within the OpenSAFELY secure analytics platform.
- 16 December 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 5, 243
Open AccessStudy protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
On March 11th 2020, the World Health Organization characterised COVID-19 as a pandemic. Responses to containing the spread of the virus have relied heavily on policies involving restricting contact between people. Evolving policies regarding shielding and individual choices about restricting social contact will rely heavily on perceived risk of poor outcomes from COVID-19. In order to make informed decisions, both individual and collective, good predictive models are required. For outcomes related to an infectious disease, the performance of any risk prediction model will depend heavily on the underlying prevalence of infection in the population of interest. Incorporating measures of how this changes over time may result in important improvements in prediction model performance. This protocol reports details of a planned study to explore the extent to which incorporating time-varying measures of infection burden over time improves the quality of risk prediction models for COVID-19 death in a large population of adult patients in England. To achieve this aim, we will compare the performance of different modelling approaches to risk prediction, including static cohort approaches typically used in chronic disease settings and landmarking approaches incorporating time-varying measures of infection prevalence and policy change, using COVID-19 related deaths data linked to longitudinal primary care electronic health records data within the OpenSAFELY secure analytics platform.
- Open Access
- 27 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae598
Quantifying and Adjusting for Confounding From Health-Seeking Behavior and Health Care Access in Observational Research
Background: Health-seeking behavior and health care access (HSB/HCA) are recognized confounders in many observational studies but are not directly measurable in electronic health records. We used proxy markers of HSB/HCA to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE). Methods: This cohort study used primary care data prelinked to secondary care and death data in England. We included individuals aged ≥66 years on 1 September 2019 and assessed influenza VE in the 2019–2020 season and early COVID-19 VE (December 2020–March 2021). VE was estimated with sequential adjustment for demographics, comorbidities, and 14 markers of HSB/HCA. Influenza vaccination in the 2019–2020 season was also considered a negative control exposure against COVID-19 before COVID-19 vaccine rollout. Results: We included 1 991 284, 1 796 667, and 1 946 943 individuals in the influenza, COVID-19, and negative control exposure populations, respectively. Markers of HSB/HCA were positively correlated with influenza and COVID-19 vaccine uptake. For influenza, adjusting for HSB/HCA markers in addition to demographics and comorbidities increased VE against influenza-like illness from −1.5% (95% CI, −3.2% to .1%) to 7.1% (95% CI, 5.4%–8.7%) with a less apparent trend for more severe outcomes. For COVID-19, adjusting for HSB/HCA markers did not change VE estimates against infection or severe disease (eg, 2 doses of BNT162b2 against infection: 82.8% [95% CI, 78.4%–86.3%] to 83.1% [95% CI, 78.7%–86.5%]). Adjusting for HSB/HCA markers removed bias in the negative control exposure analysis (−7.5% [95% CI, −10.6% to −4.5%] vs −2.1% [95% CI, −6.0% to 1.7%] before vs after adjusting for HSB/HCA markers). Conclusions: Markers of HSB/HCA can be used to quantify and account for confounding in observational vaccine studies.
- 27 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae598
Open AccessQuantifying and Adjusting for Confounding From Health-Seeking Behavior and Health Care Access in Observational Research
Background: Health-seeking behavior and health care access (HSB/HCA) are recognized confounders in many observational studies but are not directly measurable in electronic health records. We used proxy markers of HSB/HCA to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE). Methods: This cohort study used primary care data prelinked to secondary care and death data in England. We included individuals aged ≥66 years on 1 September 2019 and assessed influenza VE in the 2019–2020 season and early COVID-19 VE (December 2020–March 2021). VE was estimated with sequential adjustment for demographics, comorbidities, and 14 markers of HSB/HCA. Influenza vaccination in the 2019–2020 season was also considered a negative control exposure against COVID-19 before COVID-19 vaccine rollout. Results: We included 1 991 284, 1 796 667, and 1 946 943 individuals in the influenza, COVID-19, and negative control exposure populations, respectively. Markers of HSB/HCA were positively correlated with influenza and COVID-19 vaccine uptake. For influenza, adjusting for HSB/HCA markers in addition to demographics and comorbidities increased VE against influenza-like illness from −1.5% (95% CI, −3.2% to .1%) to 7.1% (95% CI, 5.4%–8.7%) with a less apparent trend for more severe outcomes. For COVID-19, adjusting for HSB/HCA markers did not change VE estimates against infection or severe disease (eg, 2 doses of BNT162b2 against infection: 82.8% [95% CI, 78.4%–86.3%] to 83.1% [95% CI, 78.7%–86.5%]). Adjusting for HSB/HCA markers removed bias in the negative control exposure analysis (−7.5% [95% CI, −10.6% to −4.5%] vs −2.1% [95% CI, −6.0% to 1.7%] before vs after adjusting for HSB/HCA markers). Conclusions: Markers of HSB/HCA can be used to quantify and account for confounding in observational vaccine studies.
- Open Access
- 10 June 2024
- Published by BMJ in BMJ Public Health
- Vol. 2 (1) , e000671
Herpes zoster vaccine and the risk of stroke: a population-based cohort study using linked data from the Clinical Practice Research Datalink
Background: Studies report herpes zoster associated with short-term stroke risk, but it is unclear whether herpes zoster vaccine reduces stroke risk. Methods: We performed cohort studies using Clinical Practice Research Datalink Aurum linked to hospital admission, mortality and deprivation data. We included 678 110 adults aged 70–80 years receiving a live attenuated herpes zoster vaccination between 1 September 2013 and 31 December 2019. We conducted three comparisons to a historical unvaccinated cohort, an active comparator and a self-controlled case series (SCCS). The historical cohort comprised 678 110 matched unvaccinated adults between 2007 and 2012. The active comparator comprised 653 373 adults receiving an influenza vaccination between 2013 and 2019 meeting herpes zoster vaccine eligibility. Cox regression was used to estimate HRs for stroke in the subsequent 5 years adjusted for measured confounders, in the vaccinated compared with comparator cohorts. Secondary outcomes included stroke/transient ischaemic attack and myocardial infarction. The SCCS included incident strokes 12 months before or after herpes zoster vaccination to address healthy vaccinee bias. Results: We recorded 16 281 and 30 430 incident strokes among vaccinated and unvaccinated historical patients, over a median of 2.7 and 5.0 years follow-up, respectively. The adjusted HR for stroke for herpes zoster vaccination compared with unvaccinated historical patients was 0.84 (95% CI 0.82 to 0.86) and to influenza-vaccinated patients was 0.88 (0.85 to 0.89). However, stroke incidence rates were lower in the herpes zoster-vaccinated group prevaccination compared with both comparator cohorts. The SCCS found no association between herpes zoster vaccination and stroke 30–119 days later. Conclusions: Despite our cohort study, with extensive confounder adjustment and an influenza vaccination active comparator, finding herpes zoster vaccination associated with 12%–16% reduced stroke rates, additional analyses suggested this was largely explained by healthy vaccinee bias. Our study illustrates the importance of robust sensitivity analyses and testing the suitability of causal inference tools for observational vaccine studies.
- 10 June 2024
- Published by BMJ in BMJ Public Health
- Vol. 2 (1) , e000671
Open AccessHerpes zoster vaccine and the risk of stroke: a population-based cohort study using linked data from the Clinical Practice Research Datalink
Background: Studies report herpes zoster associated with short-term stroke risk, but it is unclear whether herpes zoster vaccine reduces stroke risk. Methods: We performed cohort studies using Clinical Practice Research Datalink Aurum linked to hospital admission, mortality and deprivation data. We included 678 110 adults aged 70–80 years receiving a live attenuated herpes zoster vaccination between 1 September 2013 and 31 December 2019. We conducted three comparisons to a historical unvaccinated cohort, an active comparator and a self-controlled case series (SCCS). The historical cohort comprised 678 110 matched unvaccinated adults between 2007 and 2012. The active comparator comprised 653 373 adults receiving an influenza vaccination between 2013 and 2019 meeting herpes zoster vaccine eligibility. Cox regression was used to estimate HRs for stroke in the subsequent 5 years adjusted for measured confounders, in the vaccinated compared with comparator cohorts. Secondary outcomes included stroke/transient ischaemic attack and myocardial infarction. The SCCS included incident strokes 12 months before or after herpes zoster vaccination to address healthy vaccinee bias. Results: We recorded 16 281 and 30 430 incident strokes among vaccinated and unvaccinated historical patients, over a median of 2.7 and 5.0 years follow-up, respectively. The adjusted HR for stroke for herpes zoster vaccination compared with unvaccinated historical patients was 0.84 (95% CI 0.82 to 0.86) and to influenza-vaccinated patients was 0.88 (0.85 to 0.89). However, stroke incidence rates were lower in the herpes zoster-vaccinated group prevaccination compared with both comparator cohorts. The SCCS found no association between herpes zoster vaccination and stroke 30–119 days later. Conclusions: Despite our cohort study, with extensive confounder adjustment and an influenza vaccination active comparator, finding herpes zoster vaccination associated with 12%–16% reduced stroke rates, additional analyses suggested this was largely explained by healthy vaccinee bias. Our study illustrates the importance of robust sensitivity analyses and testing the suitability of causal inference tools for observational vaccine studies.
- Open Access
Quantifying and adjusting for confounding from health-seeking behaviour and healthcare access in observational research
Objective To assess the feasibility and effect of using proxy markers of health-seeking behaviour and healthcare access to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE). Design Cohort study for influenza VE in the 2019/2020 influenza season and for early COVID-19 VE (December 2020 – March 2021). Setting Primary care data pre-linked to secondary care and death data in England. Participants Individuals aged ≥66 years on 1 September 2019. Interventions Vaccination with any influenza vaccination in the 2019/2020 season or with either a BNT162b2 or ChAdOx1-S vaccination from 08/12/2020 to 31/03/2021. Main outcome measures Influenza or COVID-19 specific infections, hospitalisation and death. VE was estimated with sequential adjustment for demographics, underlying health conditions, and 14 markers reflecting uptake of public health interventions (screenings, vaccinations and NHS health checks), active healthcare access/use (prostate antigen testing, bone density scans, GP practice visits, low value procedures and blood pressure measurements) and lack of access/underuse (hospital visits for ambulatory care sensitive conditions and did not attend primary care visits). Influenza vaccination in the 2019/2020 season was also considered as a negative exposure intervention against the first wave of COVID-19. Results We included 1,991,284, 1,796,667, and 1,946,943 individuals in the influenza, COVID-19 and negative exposure VE populations, respectively. Vaccinated individuals were more likely to display active health-seeking behaviour, including participation in UK national screening programmes, compared with unvaccinated individuals. In the 2019/2020 influenza season, adjusting for health-seeking markers increased VE against infection from −1.5% (95%CI: −3.2,0.1) to 7.1% (95%CI: 5.4,8.7), but this trend was less apparent for more severe outcomes. For COVID-19 during early vaccine roll out, adjusting for health-seeking markers in addition to demographics and underlying health conditions did not change VE estimates against infection or severe disease (e.g., two doses of BNT162b2 against infection: from 82.8% [95%CI: 78.4,86.3] to 83.1% [95%CI: 78.7,86.5]). Adjusting for health-seeking markers removed bias in the negative exposure analysis of influenza vaccination against SARS-CoV-2 infection (−7.5% [95%CI: −10.6,-4.5] vs −2.1% [95%CI: −6.0,1.7] before vs after adjusting for health-seeking markers). Conclusions Markers of health-seeking behaviour and healthcare access can be identified in electronic health records, are associated with vaccination uptake, and can be used to quantify and account for confounding in observational studies. What is already known on this topic Health-seeking behaviour and healthcare access are recognised confounders in observational studies, but are not directly measurable in electronic health records (EHRs). Previously we systematically identified 14 markers in UK EHRs that reflect different aspects of health-seeking behaviour and healthcare access. We do not know if these markers can be utilised to quantify and account for this type of confounding in observational research using influenza and COVID-19 vaccine effectiveness as examples. What this study adds This study demonstrated using the proxy markers that confounding from health-seeking behaviour and healthcare access underestimates influenza VE estimates, but has negligible impact on COVID-19 VE estimates during early vaccine roll out. We also demonstrated via a negative exposure analysis that residual confounding can be removed by adjusting for these proxy markers.
Open AccessQuantifying and adjusting for confounding from health-seeking behaviour and healthcare access in observational research
Objective To assess the feasibility and effect of using proxy markers of health-seeking behaviour and healthcare access to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE). Design Cohort study for influenza VE in the 2019/2020 influenza season and for early COVID-19 VE (December 2020 – March 2021). Setting Primary care data pre-linked to secondary care and death data in England. Participants Individuals aged ≥66 years on 1 September 2019. Interventions Vaccination with any influenza vaccination in the 2019/2020 season or with either a BNT162b2 or ChAdOx1-S vaccination from 08/12/2020 to 31/03/2021. Main outcome measures Influenza or COVID-19 specific infections, hospitalisation and death. VE was estimated with sequential adjustment for demographics, underlying health conditions, and 14 markers reflecting uptake of public health interventions (screenings, vaccinations and NHS health checks), active healthcare access/use (prostate antigen testing, bone density scans, GP practice visits, low value procedures and blood pressure measurements) and lack of access/underuse (hospital visits for ambulatory care sensitive conditions and did not attend primary care visits). Influenza vaccination in the 2019/2020 season was also considered as a negative exposure intervention against the first wave of COVID-19. Results We included 1,991,284, 1,796,667, and 1,946,943 individuals in the influenza, COVID-19 and negative exposure VE populations, respectively. Vaccinated individuals were more likely to display active health-seeking behaviour, including participation in UK national screening programmes, compared with unvaccinated individuals. In the 2019/2020 influenza season, adjusting for health-seeking markers increased VE against infection from −1.5% (95%CI: −3.2,0.1) to 7.1% (95%CI: 5.4,8.7), but this trend was less apparent for more severe outcomes. For COVID-19 during early vaccine roll out, adjusting for health-seeking markers in addition to demographics and underlying health conditions did not change VE estimates against infection or severe disease (e.g., two doses of BNT162b2 against infection: from 82.8% [95%CI: 78.4,86.3] to 83.1% [95%CI: 78.7,86.5]). Adjusting for health-seeking markers removed bias in the negative exposure analysis of influenza vaccination against SARS-CoV-2 infection (−7.5% [95%CI: −10.6,-4.5] vs −2.1% [95%CI: −6.0,1.7] before vs after adjusting for health-seeking markers). Conclusions Markers of health-seeking behaviour and healthcare access can be identified in electronic health records, are associated with vaccination uptake, and can be used to quantify and account for confounding in observational studies. What is already known on this topic Health-seeking behaviour and healthcare access are recognised confounders in observational studies, but are not directly measurable in electronic health records (EHRs). Previously we systematically identified 14 markers in UK EHRs that reflect different aspects of health-seeking behaviour and healthcare access. We do not know if these markers can be utilised to quantify and account for this type of confounding in observational research using influenza and COVID-19 vaccine effectiveness as examples. What this study adds This study demonstrated using the proxy markers that confounding from health-seeking behaviour and healthcare access underestimates influenza VE estimates, but has negligible impact on COVID-19 VE estimates during early vaccine roll out. We also demonstrated via a negative exposure analysis that residual confounding can be removed by adjusting for these proxy markers.
- Open Access
Identifying markers of health-seeking behaviour and healthcare access in UK electronic health records
Objective: To assess the feasibility of identifying markers of health-seeking behaviour and healthcare access in UK electronic health records (EHR), for identifying populations at risk of poor health outcomes, and adjusting for confounding in epidemiological studies. Design: Cross sectional observational study using the Clinical Practice Research Datalink (CPRD) Aurum pre-linked to Hospital Episode Statistics. Setting: Individual-level routine clinical data from 13 million patients across general practices (GPs) and secondary data in England. Participants: Individuals aged ≥66 years on 01/09/2019. Main outcome measures: We used the Theory of Planned Behaviour (TPB) model and the literature to iteratively develop criteria for markers selection. Based on this we selected 15 markers: those that represented uptake of public health interventions, markers of active healthcare access/use and markers of lack of access/underuse. We calculated the prevalence of each marker using relevant lookback periods prior to index date (01/09/2019) and compared to national estimates. We assessed the correlation coefficients (phi) between markers with inferred hierarchical clustering. Results: We included 1,991,284 individuals (mean age: 75.9 and 54.0% females). The prevalence of markers ranged from <0.1% (low-value prescriptions) to 92.6% (GP visits), and most were in line with national estimates; e.g., 73.3% for influenza vaccination in the 2018/2019 season, compared to 72.4% in national estimates. Screening markers e.g., abdominal aortic aneurysm screening were under-recorded even in age-eligible groups (54.3% in 65–69 year-olds vs 76.1% in national estimates in men). Overall, marker correlations were low (<0.5) and clustered into groups according to underlying determinants from the TPB model. Conclusion: Overall, markers of health-seeking behaviour and healthcare access can be identified in UK EHRs. The generally low correlations between different markers of health-seeking behaviour and healthcare access suggest a range of variables are needed to capture different determinants of healthcare use. Strengths and limitations of this study: This is the first known study in the UK that has identified proxies or markers of health-seeking behaviour or healthcare access. We utilised linked electronic health records from primary and secondary care so that a range of different health utilisation markers could be identified. We identified a large population of over 2 million individuals. For some of the markers (e.g., bone density scans), health need could not be entirely separated from health behaviour and access. Marker prevalences showed different patterns by age, and these findings might not be generalisable to younger age groups (<65 years).
Open AccessIdentifying markers of health-seeking behaviour and healthcare access in UK electronic health records
Objective: To assess the feasibility of identifying markers of health-seeking behaviour and healthcare access in UK electronic health records (EHR), for identifying populations at risk of poor health outcomes, and adjusting for confounding in epidemiological studies. Design: Cross sectional observational study using the Clinical Practice Research Datalink (CPRD) Aurum pre-linked to Hospital Episode Statistics. Setting: Individual-level routine clinical data from 13 million patients across general practices (GPs) and secondary data in England. Participants: Individuals aged ≥66 years on 01/09/2019. Main outcome measures: We used the Theory of Planned Behaviour (TPB) model and the literature to iteratively develop criteria for markers selection. Based on this we selected 15 markers: those that represented uptake of public health interventions, markers of active healthcare access/use and markers of lack of access/underuse. We calculated the prevalence of each marker using relevant lookback periods prior to index date (01/09/2019) and compared to national estimates. We assessed the correlation coefficients (phi) between markers with inferred hierarchical clustering. Results: We included 1,991,284 individuals (mean age: 75.9 and 54.0% females). The prevalence of markers ranged from <0.1% (low-value prescriptions) to 92.6% (GP visits), and most were in line with national estimates; e.g., 73.3% for influenza vaccination in the 2018/2019 season, compared to 72.4% in national estimates. Screening markers e.g., abdominal aortic aneurysm screening were under-recorded even in age-eligible groups (54.3% in 65–69 year-olds vs 76.1% in national estimates in men). Overall, marker correlations were low (<0.5) and clustered into groups according to underlying determinants from the TPB model. Conclusion: Overall, markers of health-seeking behaviour and healthcare access can be identified in UK EHRs. The generally low correlations between different markers of health-seeking behaviour and healthcare access suggest a range of variables are needed to capture different determinants of healthcare use. Strengths and limitations of this study: This is the first known study in the UK that has identified proxies or markers of health-seeking behaviour or healthcare access. We utilised linked electronic health records from primary and secondary care so that a range of different health utilisation markers could be identified. We identified a large population of over 2 million individuals. For some of the markers (e.g., bone density scans), health need could not be entirely separated from health behaviour and access. Marker prevalences showed different patterns by age, and these findings might not be generalisable to younger age groups (<65 years).
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (5) , 685-693
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
The COVID-19 vaccines were developed and rigorously evaluated in randomized trials during 2020. However, important questions, such as the magnitude and duration of protection, their effectiveness against new virus variants, and the effectiveness of booster vaccination, could not be answered by randomized trials and have therefore been addressed in observational studies. Analyses of observational data can be biased because of confounding and because of inadequate design that does not consider the evolution of the pandemic over time and the rapid uptake of vaccination. Emulating a hypothetical "target trial" using observational data assembled during vaccine rollouts can help manage such potential sources of bias. This article describes 2 approaches to target trial emulation. In the sequential approach, on each day, eligible persons who have not yet been vaccinated are matched to a vaccinated person. The single-trial approach sets a single baseline at the start of the rollout and considers vaccination as a time-varying variable. The nature of the confounding depends on the analysis strategy: Estimating "per-protocol" effects (accounting for vaccination of initially unvaccinated persons after baseline) may require adjustment for both baseline and "time-varying" confounders. These issues are illustrated by using observational data from 2 780 931 persons in the United Kingdom aged 70 years or older to estimate the effect of a first dose of a COVID-19 vaccine. Addressing the issues discussed in this article should help authors of observational studies provide robust evidence to guide clinical and policy decisions.
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (5) , 685-693
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
The COVID-19 vaccines were developed and rigorously evaluated in randomized trials during 2020. However, important questions, such as the magnitude and duration of protection, their effectiveness against new virus variants, and the effectiveness of booster vaccination, could not be answered by randomized trials and have therefore been addressed in observational studies. Analyses of observational data can be biased because of confounding and because of inadequate design that does not consider the evolution of the pandemic over time and the rapid uptake of vaccination. Emulating a hypothetical "target trial" using observational data assembled during vaccine rollouts can help manage such potential sources of bias. This article describes 2 approaches to target trial emulation. In the sequential approach, on each day, eligible persons who have not yet been vaccinated are matched to a vaccinated person. The single-trial approach sets a single baseline at the start of the rollout and considers vaccination as a time-varying variable. The nature of the confounding depends on the analysis strategy: Estimating "per-protocol" effects (accounting for vaccination of initially unvaccinated persons after baseline) may require adjustment for both baseline and "time-varying" confounders. These issues are illustrated by using observational data from 2 780 931 persons in the United Kingdom aged 70 years or older to estimate the effect of a first dose of a COVID-19 vaccine. Addressing the issues discussed in this article should help authors of observational studies provide robust evidence to guide clinical and policy decisions.
- Open Access
- 9 January 2023
- Published by Springer Nature in Research Square
Bias assessment of a test-negative design study of COVID-19 vaccine effectiveness used in national policymaking
National test-negative-case-control (TNCC) studies are used to monitor COVID-19 vaccine effectiveness (VE) in the UK. A questionnaire was sent to participants from the first published TNCC COVID-19 VE study conducted by the UK Health Security Agency, to assess for potential biases and changes in behaviour related to vaccination. The original study included symptomatic adults aged ≥70 years testing for COVID-19 between 8 December 2020 and 21 February 2021. The questionnaire was sent to cases and controls tested from 1-21 February 2021. 8,648 individuals responded to the questionnaire (36.5% response). Self-reported timing of vaccination and infection onset was consistent with routinely recorded data. Additional adjustment of vaccine effectiveness estimates for high-risk conditions and household size or type found no evidence of confounding by these factors. Self-reported behaviour demonstrated some deferral of vaccination while unwell, but no or minimal evidence of riskier behaviour after vaccination. These findings offer reassurance to policy makers and clinicians making decisions based on COVID-19 VE TNCC studies.
- 9 January 2023
- Published by Springer Nature in Research Square
Open AccessBias assessment of a test-negative design study of COVID-19 vaccine effectiveness used in national policymaking
National test-negative-case-control (TNCC) studies are used to monitor COVID-19 vaccine effectiveness (VE) in the UK. A questionnaire was sent to participants from the first published TNCC COVID-19 VE study conducted by the UK Health Security Agency, to assess for potential biases and changes in behaviour related to vaccination. The original study included symptomatic adults aged ≥70 years testing for COVID-19 between 8 December 2020 and 21 February 2021. The questionnaire was sent to cases and controls tested from 1-21 February 2021. 8,648 individuals responded to the questionnaire (36.5% response). Self-reported timing of vaccination and infection onset was consistent with routinely recorded data. Additional adjustment of vaccine effectiveness estimates for high-risk conditions and household size or type found no evidence of confounding by these factors. Self-reported behaviour demonstrated some deferral of vaccination while unwell, but no or minimal evidence of riskier behaviour after vaccination. These findings offer reassurance to policy makers and clinicians making decisions based on COVID-19 VE TNCC studies.
- Open Access
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) covid-19 vaccines against infection and covid-19 disease in health and social care workers. Design Cohort study, emulating a comparative effectiveness trial, on behalf of NHS England. Setting Linked primary care, hospital, and covid-19 surveillance records available within the OpenSAFELY-TPP research platform, covering a period when the SARS-CoV-2 Alpha variant was dominant. Participants 317 341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a general practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable. Interventions Vaccination with either BNT162b2 or ChAdOx1 administered as part of the national covid-19 vaccine roll-out. Main outcome measures Recorded SARS-CoV-2 positive test, or covid-19 related attendance at an accident and emergency (A&E) department or hospital admission occurring within 20 weeks of receipt of the first vaccine dose. Results Over the duration of 118 771 person-years of follow-up there were 6962 positive SARS-CoV-2 tests, 282 covid-19 related A&E attendances, and 166 covid-19 related hospital admissions. The cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks after vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 20 weeks after first-dose vaccination with BNT162b2 was 21.7 per 1000 people (95% confidence interval 20.9 to 22.4) and with ChAdOx1 was 23.7 (21.8 to 25.6), representing a difference of 2.04 per 1000 people (0.04 to 4.04). The difference in the cumulative incidence per 1000 people of covid-19 related A&E attendance at 20 weeks was 0.06 per 1000 people (95% CI −0.31 to 0.43). For covid-19 related hospital admission, this difference was 0.11 per 1000 people (−0.22 to 0.44). Conclusions In this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or covid-19 disease up to 20 weeks after vaccination. Incidence dropped sharply at 3-4 weeks after vaccination, and there were few covid-19 related hospital attendance and admission events after this period. This is in line with expected onset of vaccine induced immunity and suggests strong protection against Alpha variant covid-19 disease for both vaccines in this relatively young and healthy population of healthcare workers.
Open AccessComparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) covid-19 vaccines against infection and covid-19 disease in health and social care workers. Design Cohort study, emulating a comparative effectiveness trial, on behalf of NHS England. Setting Linked primary care, hospital, and covid-19 surveillance records available within the OpenSAFELY-TPP research platform, covering a period when the SARS-CoV-2 Alpha variant was dominant. Participants 317 341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a general practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable. Interventions Vaccination with either BNT162b2 or ChAdOx1 administered as part of the national covid-19 vaccine roll-out. Main outcome measures Recorded SARS-CoV-2 positive test, or covid-19 related attendance at an accident and emergency (A&E) department or hospital admission occurring within 20 weeks of receipt of the first vaccine dose. Results Over the duration of 118 771 person-years of follow-up there were 6962 positive SARS-CoV-2 tests, 282 covid-19 related A&E attendances, and 166 covid-19 related hospital admissions. The cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks after vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 20 weeks after first-dose vaccination with BNT162b2 was 21.7 per 1000 people (95% confidence interval 20.9 to 22.4) and with ChAdOx1 was 23.7 (21.8 to 25.6), representing a difference of 2.04 per 1000 people (0.04 to 4.04). The difference in the cumulative incidence per 1000 people of covid-19 related A&E attendance at 20 weeks was 0.06 per 1000 people (95% CI −0.31 to 0.43). For covid-19 related hospital admission, this difference was 0.11 per 1000 people (−0.22 to 0.44). Conclusions In this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or covid-19 disease up to 20 weeks after vaccination. Incidence dropped sharply at 3-4 weeks after vaccination, and there were few covid-19 related hospital attendance and admission events after this period. This is in line with expected onset of vaccine induced immunity and suggests strong protection against Alpha variant covid-19 disease for both vaccines in this relatively young and healthy population of healthcare workers.